Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Division of Perioperative Medicine, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japa.
Nagoya J Med Sci. 2022 Feb;84(1):200-207. doi: 10.18999/nagjms.84.1.200.
Surgical resection is the mainstay of treatment for retroperitoneal liposarcoma (RPLS). Herein, we describe a case of dedifferentiated RPLS successfully treated with an extended surgical approach with adjuvant chemotherapy. A 61-year-old male was referred to our hospital with a chief complaint of chest tightness. Abdominal computed tomography revealed a large retroperitoneal tumor, 11 cm in diameter, extensively invading the surrounding organs: the celiac axis, the splenic artery, the pancreatic body and tail, the lesser curvature of the stomach and the left adrenal gland. Endoscopic ultrasound-guided fine-needle aspiration biopsy confirmed dedifferentiated liposarcoma, suggesting aggressive tumor biology. We performed total gastrectomy combined with distal pancreatectomy with celiac axis and left adrenal gland resection with a curative intent. The postoperative course was almost uneventful. As the pathological findings indicated a positive margin with a well-differentiated liposarcoma component, we added adjuvant chemotherapy with four cycles of doxorubicin and ifosfamide (AI). Five years after primary surgery, regular follow-up CT demonstrated a pulmonary hilar lymph node enlargement and a tumor at paraesophageal locations. After downsizing chemotherapy with eribulin followed by pazopanib, he underwent partial esophagectomy with dissection of the paraesophageal tumor. The pathological findings indicated recurrence of dedifferentiated liposarcoma with a tumor-free surgical margin. He is currently alive without any evidence of recurrence almost 7 years after the first surgery and 15 months after the second surgery. The long-term survival gained in this patient indicates that extended resections and adjuvant chemotherapy could prolong survival in patients even with RPLS with dedifferentiated tumor histology.
手术切除是治疗腹膜后脂肪肉瘤(RPLS)的主要方法。在此,我们描述了 1 例采用扩展手术方法联合辅助化疗成功治疗去分化脂肪肉瘤的病例。1 名 61 岁男性因胸闷主诉就诊于我院。腹部 CT 显示腹膜后巨大肿瘤,直径 11cm,广泛侵犯周围器官:腹腔干、脾动脉、胰体尾、胃小弯和左肾上腺。内镜超声引导下细针穿刺活检证实为去分化脂肪肉瘤,提示肿瘤具有侵袭性生物学行为。我们采用根治性手术方法行全胃切除术联合远端胰腺切除术、腹腔干和左肾上腺切除术。术后过程几乎无并发症。由于病理检查发现存在阳性切缘且有分化良好的脂肪肉瘤成分,我们加用多柔比星和异环磷酰胺(AI)4 个周期的辅助化疗。初次手术后 5 年,定期随访 CT 显示肺门淋巴结肿大和食管旁部位肿瘤。在接受表柔比星和帕唑帕尼缩小化疗后,他接受了部分食管切除术和食管旁肿瘤切除术。病理检查结果表明为去分化脂肪肉瘤复发,且手术切缘无肿瘤。目前患者无复发迹象,初次手术后近 7 年,二次手术后 15 个月,仍存活。该患者的长期生存表明,即使对于具有去分化肿瘤组织学特征的 RPLS 患者,扩大切除术和辅助化疗也可以延长生存时间。